Table 3.
Multivariate Analysis of Prognostic factors of BCSS and OS in Metastatic Breast Cancer
| Characteristic | BCSS | OS | ||||
|---|---|---|---|---|---|---|
| HR | 95%CI | p | HR | 95%CI | p | |
| Age | 1.01 | 1.008–1.013 | < 0.001 | 1.018 | 1.016–1.020 | < 0.001 |
| Race | ||||||
| White | 1 | 1 | ||||
| Black | 1.074 | 0.985–1.171 | 0.104 | 1.262 | 1.171–1.360 | < 0.001 |
| Others | 0.932 | 0.819–1.061 | 0.286 | 1.011 | 0.902–1.133 | 0.85 |
| Marital status | ||||||
| Married | 1 | 1 | ||||
| Unmarried | 1.1 | 1.026–1.178 | 0.007 | 1.244 | 1.172–1.320 | < 0.001 |
| Grade | ||||||
| I | 1 | 1 | ||||
| II | 1.199 | 1.031–1.396 | 0.0019 | 1.353 | 1.197–1.530 | < 0.001 |
| III & IV | 1.372 | 1.177–1.599 | < 0.001 | 1.803 | 1.590–2.043 | < 0.001 |
| BC Subtype | ||||||
| HR+/HER2- | 1 | 1 | ||||
| HR+/HER2+ | 1.084 | 0.979–1.201 | 0.12 | 0.876 | 0.800–0.959 | 0.004 |
| HR−/HER2+ | 1.363 | 1.196–1.553 | < 0.001 | 1.15 | 1.026–1.289 | 0.017 |
| Triple negative | 2.12 | 1.925–2.335 | < 0.001 | 2.823 | 2.596–3.069 | < 0.001 |
| Stage T | ||||||
| T0/T1 | 1 | 1 | ||||
| T2 | 1.019 | 0.906–1.147 | 0.748 | 0.997 | 0.908–1.094 | 0.948 |
| T3 | 1.048 | 0.921–1.191 | 0.478 | 1.053 | 0.948–1.170 | 0.332 |
| T4 | 1.189 | 1.059–1.334 | 0.003 | 1.227 | 1.118–1.348 | < 0.001 |
| Stage N | ||||||
| N0 | 1 | 1 | ||||
| N1 | 0.923 | 0.841–1.014 | 0.095 | 0.926 | 0.856–1.001 | 0.054 |
| N2 | 0.863 | 0.761–0.978 | 0.021 | 1.072 | 0.962–1.194 | 0.208 |
| N3 | 0.929 | 0.844–1.023 | 0.136 | 1.064 | 0.980–1.154 | 0.138 |
| Surgery | ||||||
| No | 1 | 1 | ||||
| Yes | 0.733 | 0.680–0.790 | < 0.001 | 0.595 | 0.558–0.634 | < 0.001 |
| Radiotherapy | ||||||
| No | 1 | 1 | ||||
| Yes | 0.898 | 0.837–0.964 | 0.003 | 0.981 | 0.922–1.042 | 0.528 |
| Chemotherapy | ||||||
| No/Unknown | 1 | 1 | ||||
| Yes | 0.685 | 0.634–0.741 | < 0.001 | 0.682 | 0.638–0.730 | < 0.001 |
| Metastatic site | ||||||
| Bone | 1 | 1 | ||||
| Lung | 0.994 | 0.881–1.122 | 0.921 | 0.994 | 0.897–1.100 | 0.902 |
| Liver | 1.384 | 1.208–1.586 | < 0.001 | 1.428 | 1.272–1.602 | < 0.001 |
| Brain | 1.975 | 1.551–2.514 | < 0.001 | 2.307 | 1.862–2.859 | < 0.001 |
| Other | 0.955 | 0.827–1.103 | 0.532 | 1.127 | 1.001–1.269 | 0.048 |
| Multiple | 1.475 | 1.361–1.599 | < 0.001 | 1.806 | 1.684–1.937 | < 0.001 |
Abbreviations: BCSS breast cancer–specific survival, OS overall survival, HR hazard ratio, CI confidence interval, BC breast cancer, HR hormone receptor, HER2 human epidermal growth receptor 2, TN triple negative